Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP10 Elbasvir
D10625 Elbasvir (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
DG01999 HCV NS5A inhibitor
D10625 Elbasvir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D10625 Elbasvir
Transporter substrate
DG01665 ABCB1 substrate
D10625 Elbasvir
Transporter inhibitor
DG01622 ABCB1 inhibitor
D10625 Elbasvir
DG02862 ABCG2 inhibitor
D10625 Elbasvir
Antimicrobials [BR:br08307]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D10625 Elbasvir (JAN/USAN/INN)
Antimicrobials abbreviations [BR:br08327]
Antivirals
Genome replication inhibitor
HCV NS5A/NS5B inhibitor
D10625 Elbasvir (JAN/USAN/INN)
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10625
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10625
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10625
Drug transporters
D10625